ArticleFrontiers in oncology2025
CDK1 may promote breast cancer progression through AKT activation and immune modulation.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics profiling identifies CDK1 as a key mediator of mitosis through the PTN pathway in bladder cancer.Future science OA · 2026Article
- An Integrated Cellular Computational Pipeline Decodes Luteolin to Design Possible Allosteric CDK1/CYCLIN B1 Inhibitors That Overcome Breast Cancer Stemness.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cyclin-dependent kinase 1 (CDK1) plays a crucial role in regulating the cell cycle, yet its clinical relevance and molecular mechanisms in breast cancer remain insufficiently characterized. This study aimed to comprehensively evaluate CDK1 expression, prognostic value, and biological functions in breast cancer through integrated bioinformatics and experimental analyses. Methods: Transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) were analyzed to assess CDK1 expression, diagnostic efficacy, and survival associations. Immune infiltration and tumor mutation burden (TMB) were evaluated using TIMER and CIBERSORT algorithms. Single-cell RNA sequencing data from TISCH2 were employed to examine cell-type-specific expression. Functional experiments, including shRNA-mediated CDK1 knockdown, Western blotting, and CCK-8 assays, were performed to validate its biological role in MDA-MB-231 cells. Results: CDK1 expression was elevated in breast cancer tissues compared with normal controls and exhibited high diagnostic accuracy (AUC = 0.978). Elevated CDK1 levels were associated with HER2-, ER-, and PR-negative subtypes and enriched in Basal-like breast cancer. Patients with high CDK1 expression showed poorer disease-specific survival (HR = 1.67, p = 0.024). Immune analysis revealed positive correlations between CDK1 and immune cell infiltration, particularly CD4+ memory T cells, CD8+ T cells, etc. as well as a moderate association with TMB. Single-cell analysis indicated that CDK1 was preferentially expressed in CD8+ T cells and M1 macrophages. Mechanistically, CDK1 knockdown reduced AKT phosphorylation and downregulated Cyclin D1, A, and E1, leading to suppressed proliferation of breast cancer cells. Conclusion: CDK1 acts as a multifaceted oncogenic factor in breast cancer, contributing to tumor growth and immune modulation. Its overexpression is linked to poor prognosis and enhanced immune infiltration, underscoring its potential as a diagnostic and therapeutic target. Targeting CDK1 or its downstream signaling pathways may offer novel strategies, particularly for aggressive subtypes such as Basal-like or triple-negative breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.